Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery.

Autor: Martín-Escolano R; Laboratory of Molecular & Evolutionary Parasitology, RAPID Group, School of Biosciences, University of Kent, Canterbury CT2 7NJ, UK. Electronic address: r.martin-escolano@kent.ac.uk., Rosales MJ; Department of Parasitology, University of Granada, Severo Ochoa s/n, Granada 18071, Spain., Marín C; Department of Parasitology, University of Granada, Severo Ochoa s/n, Granada 18071, Spain. Electronic address: cmaris@ugr.es.
Jazyk: angličtina
Zdroj: Acta tropica [Acta Trop] 2022 Dec; Vol. 236, pp. 106679. Date of Electronic Publication: 2022 Sep 09.
DOI: 10.1016/j.actatropica.2022.106679
Abstrakt: Trypanosoma cruzi, the causative agent of Chagas disease (CD), is a genuine parasite with tremendous genetic diversity and a complex life cycle. Scientists have studied this disease for more than 100 years, and CD drug discovery has been a mainstay due to the absence of an effective treatment. Technical advances in several areas have contributed to a better understanding of the complex biology and life cycle of this parasite, with the aim of designing the ideal profile of both drug and therapeutic options to treat CD. Here, we present the T. cruzi Arequipa strain (MHOM/Pe/2011/Arequipa) as an interesting model for CD drug discovery. We characterized acute-phase parasitaemia and chronic-phase tropism in BALB/c mice and determined the in vitro and in vivo benznidazole susceptibility profile of the different morphological forms of this strain. The tropism of this strain makes it an interesting model for the screening of new compounds with a potential anti-Chagas profile for the treatment of this disease.
Competing Interests: Declaration of Competing Interest The authors declare that they have no conflicts of interests.
(Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: